
    <!doctype html>

    <html lang="en">
    <head>
        <meta charset="utf-8">    
        <script type="text/JavaScript" src="https://MomentJS.com/downloads/moment.js"></script>
        <script type="text/JavaScript" src="https://momentjs.com/downloads/moment-timezone-with-data.min.js"></script>
        <title>Transthyretin and Alzheimer’s disease: Systematic review</title>
        <style>
            
    * {
        font-family: "Trebuchet MS", Helvetica, sans-serif;
    }
    
        </style>
        <script type="text/JavaScript">
            
	function LT(t) {
        var m = moment.utc(t).tz(moment.tz.guess());
		document.write(m.format('MMMM Do YYYY, HH:mm z'));
	};
    function time_between(start, end) {
        var s = moment.utc(start);
        var e = moment.utc(end);
        var now = moment();
        return (s<=now) && (now<=e);
    };
    function update_visibility() {
        var now = moment();
        var elems = document.getElementsByClassName("visible_at_time");
        for(var i=0; i<elems.length; i++) {
            s = moment.utc(elems[i].dataset.start);
            e = moment.utc(elems[i].dataset.end);
            if ( (s<=now) && (now<=e) ) {
                elems[i].style.display = "block";
            } else {
                elems[i].style.display = "none";
            }
        }
    };
    setInterval(update_visibility, 60*1000);
    
        </script>
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
    </head>
    <body>
        <h3>
            <a href="https://neuromatch.io">Neuromatch</a> 3 /
            <script type="text/JavaScript">LT("2020-10-30 12:15");</script>
            /
            Track 6
            /
            Interactive talk
            <div class="visible_at_time" data-start="2020-10-30 12:15" data-end="2020-10-30 12:30">
                <a href='https://www.youtube.com/watch?v=Ic6pNxh9cuU'><i class="fa fa-youtube-play" style="font-size:24px;color:red"></i></a>
                <a href='https://www.youtube.com/watch?v=Ic6pNxh9cuU'>Watch now on YouTube</a>
            </div>
        </h3>
        <h1>Transthyretin and Alzheimer’s disease: Systematic review</h1><h2>Arjumand Faruqi</h2><h3>Ahmad Ozair </h3><h2>Abstract</h1><p>Introduction:<br/>Prealbumin or transthyretin (TTR), a protein, is found in various tissues, including the brain. [1]<br/>Studies have found a conflicting role of TTR in Alzheimer’s Disease (AD). [1-3]<br/>No systematic review, the highest quality of evidence, currently exists on this. Only narrative reviews exist.<br/><br/> Material and methods:<br/>1. We conducted the systematic review as per the PRISMA checklist and flowchart<br/>We conducted a search on PUBMED/ MEDLINE database on 15th June 2020.<br/>2. We used the search function: ((transthyretin) OR (prealbumin)) AND (Alzheimer's disease)<br/>3. We found 95 eligible studies after the three steps of screening.<br/>Identification: Records identified through database searching (PUBMED) (n=346). Additional records identified through other sources (n=0). Duplicate Removal: Records after duplicates removed (n=346).<br/>Screening:<br/>  Records screened (n = 346), Records excluded (n=184).<br/>  Full-text articles assessed for eligibility (n =162). Full-text articles excluded, with reasons (n=67).<br/>Included- Studies included in qualitative synthesis (n=95).<br/><br/>Results:<br/>Majority of studies find that TTR has an overall neuroprotective role in AD.<br/>TTR has been found to clear Amyloid-beta (Aβ) peptide molecules and inhibit Aβ aggregation.<br/>TTR is found to influence A-beta levels in a gender-specific manner, its action influenced by testosterone and estradiol.<br/>There is enough evidence to suggest that TTR in cerebrospinal fluid (CSF) comes from 3 sources: (1) synthesis by neurons, (2) synthesis by choroid plexus; and (3) serum TTR also diffuses into the CSF.<br/>Studies done in CSF report that TTR levels in CSF are significantly decreased in AD.<br/>In CSF of patients with AD, abundant oxidized iOS forms of TTR are detected.<br/>Studies done in serum also find that TTR levels inversely correlate with disease progression. Serum TTR levels are found to be lowered in AD patients.<br/>Serum levels of TTR have been found to be a good biomarker for AD for diagnostics.<br/><br/>Discussion:<br/>We could not perform quantitative synthesis due to lack of large observational or interventional studies in clinical practice.<br/>We only searched the PUBMED/MEDLINE database, and did not utilise SCOPUS or EMBASE.<br/><br/>References:<br/>1. Pate KM, Murphy RM. Cerebrospinal Fluid Proteins as Regulators of Beta-amyloid Aggregation and Toxicity. Isr J Chem. 2017;57(7-8):602-612. doi:10.1002/ijch.201600078<br/>2.  P, Russo C. Human brain amyloidoses. Nephrol Dial Transplant. 1998;13 S7:33-40.<br/>3. Chodobski A, Szmydynger-Chodobska J. Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech. 2001;52(1):65-82.<br/></p>
        <script type="text/JavaScript">
            update_visibility();
        </script>
    </body>
    </html>
    